Tag: GlobeNewswire

Please find herewith the press release.

Attachment

• p261005E – Publication of a transparency notification

Bernin, October 5, 2026

INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL

(Article L. 233-8 II of the French Commercial Code
and article 223-16 of the General Regulation of the French Financial Markets Authority (AMF))

Corporate name and address of the company: SOITEC
Parc Technologique des Fontaines – Chemin des Franques
38190 Bernin (FRANCE)

Statement date	Total number of shares forming the share capital	Total number of voting rights
09/30/2026	35,814,320(1)	Number of theoretical (gross) voting rights (2): 44,779,122
		Number of exercisable (net) voting rights (3): 44,756,659

1. 35,814,320 ordinary shares of €2.00 par value each, listed on the Euronext Paris regulated market under ISIN code FR0013227113 and the mnemonic “SOI”.
2. The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with article 223-11 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers – AMF), this number is calculated on the basis of all shares to which single or double voting rights are attached, including shares without voting rights (for example, treasury shares, liquidity contract, etc.). 
3. The total number of exercisable voting rights (or “net” voting rights) is calculated after taking into account the number of shares entitled to double voting rights, and after deduction of the shares without voting rights (for example, treasury shares, liquidity contract, etc.).

*****

 About Soitec

Soitec (Euronext – Tech Leaders – SBF 120), a world leader in innovative semiconductor materials, has been developing cutting-edge products delivering both technological performance and energy efficiency for over 30 years. From its global headquarters in France, Soitec is expanding internationally with its unique solutions, and generated sales of around 600 million euros in fiscal year 2025-2026. Soitec occupies a key position in the semiconductor value chain, serving three main strategic markets: Mobile Communications, Automotive and Industrial, and Edge and Cloud AI. The company relies on the talent and diversity of nearly 2,000 employees, representing 50 different nationalities, working at its sites in Europe, the United States and Asia. Nearly 4,800 patents have been registered by Soitec.

Soitec, SmartSiC™ and Smart Cut™ are registered trademarks of Soitec.

For more information soitec.com and follow us on LinkedIn and X:  @Soitec_Official

*****

Investor Relations: investors@soitec.com

Media Relations: media@soitec.com

Attachment

• SOITEC-DDV-September-2026

Bernin, October 5, 2026

INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL

(Article L. 233-8 II of the French Commercial Code
and article 223-16 of the General Regulation of the French Financial Markets Authority (AMF))

Corporate name and address of the company: SOITEC
Parc Technologique des Fontaines – Chemin des Franques
38190 Bernin (FRANCE)

Statement date	Total number of shares forming the share capital	Total number of voting rights
09/30/2026	35,814,320(1)	Number of theoretical (gross) voting rights (2): 44,779,122
		Number of exercisable (net) voting rights (3): 44,756,659

1. 35,814,320 ordinary shares of €2.00 par value each, listed on the Euronext Paris regulated market under ISIN code FR0013227113 and the mnemonic “SOI”.
2. The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with article 223-11 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers – AMF), this number is calculated on the basis of all shares to which single or double voting rights are attached, including shares without voting rights (for example, treasury shares, liquidity contract, etc.). 
3. The total number of exercisable voting rights (or “net” voting rights) is calculated after taking into account the number of shares entitled to double voting rights, and after deduction of the shares without voting rights (for example, treasury shares, liquidity contract, etc.).

*****

 About Soitec

Soitec (Euronext – Tech Leaders – SBF 120), a world leader in innovative semiconductor materials, has been developing cutting-edge products delivering both technological performance and energy efficiency for over 30 years. From its global headquarters in France, Soitec is expanding internationally with its unique solutions, and generated sales of around 600 million euros in fiscal year 2025-2026. Soitec occupies a key position in the semiconductor value chain, serving three main strategic markets: Mobile Communications, Automotive and Industrial, and Edge and Cloud AI. The company relies on the talent and diversity of nearly 2,000 employees, representing 50 different nationalities, working at its sites in Europe, the United States and Asia. Nearly 4,800 patents have been registered by Soitec.

Soitec, SmartSiC™ and Smart Cut™ are registered trademarks of Soitec.

For more information soitec.com and follow us on LinkedIn and X:  @Soitec_Official

*****

Investor Relations: investors@soitec.com

Media Relations: media@soitec.com

Attachment

• SOITEC-DDV-September-2026

Two oral presentations at AHA Hypertension 2026 will highlight the substantial antihypertensive efficacy of aprocitentan in two hypertension populations from the PRECISION study: patients with obesity and patients across the cardiovascular-kidney-metabolic (CKM) continuum.

The analyses extend the clinical evidence supporting aprocitentan in these patients and further underscore the importance of blockade of the upregulated endothelin system as a therapeutic target in difficult-to-control hypertension, including true resistant hypertension.

Allschwil, Switzerland – October 5, 2026
Idorsia Ltd (SIX: IDIA) announces positive findings from two new analyses of the pivotal Phase 3 PRECISION study highlighting the importance of endothelin pathway blockade in patients with obesity-associated resistant hypertension and across the cardiovascular-kidney-metabolic continuum. The findings will be presented in oral sessions at the American Heart Association Hypertension Scientific Sessions 2026, taking place in Arlington, Virginia, from October 7 to 11, 2026.

Targeting the upregulated endothelin pathway in patients with obesity and hypertension
Obesity and hypertension are closely interconnected. Hypertension is one of the most common comorbidities of obesity and is a major contributor to cardiovascular and kidney damage in this population. As the prevalence of obesity continues to rise, the number of people living with obesity-associated hypertension is also expected to increase.¹

The obese population is more likely to develop hypertension that remains uncontrolled despite treatment with multiple antihypertensive medicines. The upregulation of the endothelin pathway appears to be an important system that had not been targeted in hypertension before aprocitentan. Adipose tissue releases endothelin-1, with greater release observed in obese people.¹ Obesity is therefore associated with increased detrimental effects of endothelin-1.^1-2
A new analysis of PRECISION evaluated aprocitentan in patients with resistant hypertension and obesity or severe obesity, many of whom were also living with diabetes, chronic kidney disease or albuminuria. The positive findings strengthen the evidence supporting endothelin pathway blockade in this population and provide new insights into the role of endothelin in obesity-associated resistant hypertension.

The results will be presented for the first time in an oral presentation by Dr. Michael A. Weber, MD:
Endothelin is a driver of hypertension in individuals with obesity: A post hoc analysis of the PRECISION study.
Markus Schlaich, Martine Clozel, Ruth Collins, Parisa Danaietash, John M. Flack, Johann Laurent, Krzysztof Narkiewicz, Ji-Guang Wang, and Michael A. Weber.
Saturday, October 10, 5:15 PM | Abstract Session 19 | Number 83

Targeting the upregulated endothelin pathway in patients with CKM and hypertension
Cardiovascular-kidney-metabolic (CKM) syndrome is defined as a health disorder attributable to the interconnections among obesity, diabetes, chronic kidney disease, and cardiovascular disease.^3,4 The risk of cardiovascular death nearly triples as CKM progresses from stages 0-1 to stage 4, while more than 64% of the US adult population is classified as CKM stages 2 to 4.³ Hypertension is a central driver across this continuum, contributing to chronic kidney disease progression, while dysfunction in the cardiovascular, kidney, and metabolic systems creates a self-reinforcing cycle that increases the risk of cardiovascular events, kidney failure, hospitalization and premature death.^3-5
Endothelin has detrimental consequences relevant to multiple components of CKM syndrome, including blood pressure regulation, kidney function and metabolic effects such as aldosterone production. This provides a strong rationale for examining endothelin inhibition across different stages of CKM syndrome.

A new analysis of PRECISION evaluated aprocitentan across early and advanced CKM stages. The positive findings further characterize the effects of endothelin pathway blockade across the CKM continuum and provide new insights into blood pressure control and other measures relevant to cardiovascular, kidney and metabolic health.

The findings will be presented for the first time in an oral session at the congress by Dr. John M. Flack, MD:
Endothelin as a therapeutic target across the cardiovascular-kidney-metabolic continuum: A post hoc analysis of the PRECISION study
Markus Schlaich, Martine Clozel, Parisa Danaietash, Johann Laurent, Alessandro Maresta, Krzysztof Narkiewicz, Ji-Guang Wang, Michael A. Weber, and John M. Flack.
Saturday, October 10, 2:30 PM | Abstract session 17 | Number 72

Join Idorsia at leading cardiovascular and kidney congresses
Idorsia will also be present at major US congresses, where it will host exhibitor spotlight sessions on “The Next Era in the Treatment of Hypertension.”

• AHA Hypertension, Crystal City, VA, October 8-10. Visit us at Tables 25 and 26. Exhibitor Spotlight at Ballroom A & B on Friday, October 9, from 1:00 to 1:30 p.m.
• ASN Kidney Week, Denver, CO, October 22-24. Visit us at Booth #1023. Exhibitor Spotlight at Theater #3 on Saturday, October 24, from 11:00 to 11:45 a.m.
• AHA Scientific Sessions, Chicago, IL, November 7-9. Visit us at Booth #3014. Exhibitor Spotlight at Learning Studio #3 on Sunday, November 8, from 9:30 to 10:15 a.m.

Notes to the editor

About Dr Michael A. Weber, MD
Dr. Weber is Professor of Medicine at the SUNY Downstate College of Medicine in Brooklyn, New York. He received his medical degree from Sydney University in Australia. His career has been focused primarily on hypertension and preventive cardiology. He has published numerous research articles in medical literature and has authored or edited several books.

Dr. Weber was the Editor-in-Chief of The Journal of Clinical Hypertension for over 10 years. Dr. Weber was one of the founders of The American Society of Hypertension and has served as its President. He also served as Chair of the ASH Hypertension Specialists Program. He is a Fellow of The American College of Physicians, The American College of Cardiology and The American Heart Association. He has served on the Cardiovascular and Renal Drugs Advisory Board of the Food and Drug Administration. He has also served for ten years as Chairman of the Formulary Committee of a major pharmacy benefits provider serving many of the leading health plans in the United States.

His main current research interests are in clinical trials of patients at high risk of cardiovascular events or strokes. He is also participating actively in trials in patients with metabolic disorders such as diabetes and kidney disease. Dr. Weber currently serves on the Steering Committees of several national and international clinical trials. Dr. Weber serves as a consultant to Idorsia.

About Dr. John M. Flack, MD
Dr. Flack, an Alpha Omega Alpha (AOA) graduate of the University of Oklahoma School of Medicine, is the Sergio Rabinovich Endowed Chair of Internal Medicine and the Professor and Chair of the Departments of Medicine and Population Science at Southern Illinois University School of Medicine. He is also Director of the Hypertension Clinic.

He is a board-certified Internal Medicine specialist and an internationally renowned hypertension specialist/cardiovascular epidemiologist with widely recognized clinical/research expertise in hypertension in African Americans, resistant/refractory hypertension, device-based therapies for hypertension and racial cardiovascular health disparities. Dr. Flack is the current President of the American Hypertension Specialist Certification Program. He has published over 250 peer-reviewed manuscripts and book chapters and is an Associate Editor for the journal Hypertension. He maintains an active clinical practice in complex hypertension at SIU where he teaches and mentors medical students and residents and undertakes innovative, cutting-edge research.

Dr. Flack has received numerous awards including the Distinguished Research Award (1993) from the International Society on Hypertension in Blacks (ISHIB), the Daniel D. Savage Memorial Scientific Award (1998) from the Association of Black Cardiologist (ABC), the F. Dewey Dodrill Award for Excellence (2007) from the American Heart Association (AHA), the Detroit News Michiganian of the Year (2009), and the University of Oklahoma Academic Physician of the Year (2012). Also, he has been repeatedly named to Top Doctor, Best Doctor, and Super Doctor lists. Previously, he served as a voting member of the FDA Cardio-Renal Advisory Board. Dr. Flack was recently conferred the status of Master by the American College of Physicians (ACP); he also previously served as a member of the ACP Board of Regents. Dr. Flack serves as a consultant to Idorsia.

About aprocitentan
Aprocitentan is a once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan is approved as TRYVIO^® in the US for the treatment of systemic hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs, and has been commercially available since October 2024. For more information see the Full Prescribing Information including BOXED Warning (PI and Medication Guide). TRYVIO is now included in the American College of Cardiology’s (ACC) and the American Heart Association’s (AHA) new comprehensive clinical practice guidelines for the management of high blood pressure. Aprocitentan is approved as JERAYGO^™ for the treatment of resistant hypertension in combination with other antihypertensives in the European Union, the UK, Switzerland, and Canada.

About PRECISION^6,7 (NCT03541174)
PRECISION was a multicenter, blinded, randomized, parallel-group, Phase 3 study, which was performed in Europe, North America, Asia, and Australia. Patients were eligible for randomization if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardized background therapy consisting of three antihypertensive drugs, including a diuretic. The study consisted of three sequential parts: Part 1 was the 4-week double-blind, randomized, and placebo-controlled part, in which 730 patients were randomized to aprocitentan 12.5 mg (n=243), aprocitentan 25 mg (n=243), or placebo (n=244) in a 1:1:1 ratio; Part 2 was a 32-week single (patient)-blind part, in which all patients received aprocitentan 25 mg (n=704); and Part 3 was a 12-week double-blind, randomized, and placebo-controlled withdrawal part, in which patients were re-randomized to aprocitentan 25 mg (n=307) or placebo (n=307) in a 1:1 ratio. The primary and key secondary endpoints were changes in unattended office systolic blood pressure from baseline to week 4 and from withdrawal baseline to week 40, respectively. Secondary endpoints included 24-h ambulatory blood pressure changes.

At baseline, 69.2% of patients were obese or severely obese, 54.1% had diabetes, 22.2% had stage 3-4 chronic kidney disease and 19.6% had congestive heart failure. 63% of randomized patients were receiving at least 4 anti-hypertensive therapies at screening.

References

1. Parvanova A, et al. Mechanisms and treatment of obesity-related hypertension. Part 2: Treatments. Clin Kidney J. 2025;18(3):sfaf035. doi:10.1093/ckj/sfaf035.
2. Weil BR, et al. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol. 2011;301(3):H689-H695. doi:10.1152/ajpheart.00206.2011.
3. Mavromatis LA, et al. Epidemiology of cardiovascular-kidney-metabolic syndrome. Nat Rev Nephrol. Published online May 7, 2026. doi:10.1038/s41581-026-01078-w.
4. Chen Y, et al. Prevalence and mortality association of different stages of cardiovascular-kidney-metabolic syndrome. JACC Adv. 2025;4(6 Pt 2):101843. doi:10.1016/j.jacadv.2025.101843.
5. McCormack T, et al. Uncontrolled Hypertension Prevalence, Characteristic Profiles, and Risk of Cardiorenal and Metabolic Outcomes: Insights from the EnligHTN Study. Adv Ther. Published online July 13, 2026. doi:10.1007/s12325-026-03681-6
6. Danaietash P et al. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertension 2022 Jul;24(7):804-813.
7. Schlaich MP, et al. A randomized controlled trial of the dual endothelin antagonist aprocitentan for resistant hypertension. The Lancet, 2022; Dec 3;400(10367):1927-1937.

About Idorsia
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Idorsia has transferred its rights for aprocitentan, cenerimod and selatogrel to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the latest Financial Report.

Attachment

• Press Release PDF

Two oral presentations at AHA Hypertension 2026 will highlight the substantial antihypertensive efficacy of aprocitentan in two hypertension populations from the PRECISION study: patients with obesity and patients across the cardiovascular-kidney-metabolic (CKM) continuum.

The analyses extend the clinical evidence supporting aprocitentan in these patients and further underscore the importance of blockade of the upregulated endothelin system as a therapeutic target in difficult-to-control hypertension, including true resistant hypertension.

Allschwil, Switzerland – October 5, 2026
Idorsia Ltd (SIX: IDIA) announces positive findings from two new analyses of the pivotal Phase 3 PRECISION study highlighting the importance of endothelin pathway blockade in patients with obesity-associated resistant hypertension and across the cardiovascular-kidney-metabolic continuum. The findings will be presented in oral sessions at the American Heart Association Hypertension Scientific Sessions 2026, taking place in Arlington, Virginia, from October 7 to 11, 2026.

Targeting the upregulated endothelin pathway in patients with obesity and hypertension
Obesity and hypertension are closely interconnected. Hypertension is one of the most common comorbidities of obesity and is a major contributor to cardiovascular and kidney damage in this population. As the prevalence of obesity continues to rise, the number of people living with obesity-associated hypertension is also expected to increase.¹

The obese population is more likely to develop hypertension that remains uncontrolled despite treatment with multiple antihypertensive medicines. The upregulation of the endothelin pathway appears to be an important system that had not been targeted in hypertension before aprocitentan. Adipose tissue releases endothelin-1, with greater release observed in obese people.¹ Obesity is therefore associated with increased detrimental effects of endothelin-1.^1-2
A new analysis of PRECISION evaluated aprocitentan in patients with resistant hypertension and obesity or severe obesity, many of whom were also living with diabetes, chronic kidney disease or albuminuria. The positive findings strengthen the evidence supporting endothelin pathway blockade in this population and provide new insights into the role of endothelin in obesity-associated resistant hypertension.

The results will be presented for the first time in an oral presentation by Dr. Michael A. Weber, MD:
Endothelin is a driver of hypertension in individuals with obesity: A post hoc analysis of the PRECISION study.
Markus Schlaich, Martine Clozel, Ruth Collins, Parisa Danaietash, John M. Flack, Johann Laurent, Krzysztof Narkiewicz, Ji-Guang Wang, and Michael A. Weber.
Saturday, October 10, 5:15 PM | Abstract Session 19 | Number 83

Targeting the upregulated endothelin pathway in patients with CKM and hypertension
Cardiovascular-kidney-metabolic (CKM) syndrome is defined as a health disorder attributable to the interconnections among obesity, diabetes, chronic kidney disease, and cardiovascular disease.^3,4 The risk of cardiovascular death nearly triples as CKM progresses from stages 0-1 to stage 4, while more than 64% of the US adult population is classified as CKM stages 2 to 4.³ Hypertension is a central driver across this continuum, contributing to chronic kidney disease progression, while dysfunction in the cardiovascular, kidney, and metabolic systems creates a self-reinforcing cycle that increases the risk of cardiovascular events, kidney failure, hospitalization and premature death.^3-5
Endothelin has detrimental consequences relevant to multiple components of CKM syndrome, including blood pressure regulation, kidney function and metabolic effects such as aldosterone production. This provides a strong rationale for examining endothelin inhibition across different stages of CKM syndrome.

A new analysis of PRECISION evaluated aprocitentan across early and advanced CKM stages. The positive findings further characterize the effects of endothelin pathway blockade across the CKM continuum and provide new insights into blood pressure control and other measures relevant to cardiovascular, kidney and metabolic health.

The findings will be presented for the first time in an oral session at the congress by Dr. John M. Flack, MD:
Endothelin as a therapeutic target across the cardiovascular-kidney-metabolic continuum: A post hoc analysis of the PRECISION study
Markus Schlaich, Martine Clozel, Parisa Danaietash, Johann Laurent, Alessandro Maresta, Krzysztof Narkiewicz, Ji-Guang Wang, Michael A. Weber, and John M. Flack.
Saturday, October 10, 2:30 PM | Abstract session 17 | Number 72

Join Idorsia at leading cardiovascular and kidney congresses
Idorsia will also be present at major US congresses, where it will host exhibitor spotlight sessions on “The Next Era in the Treatment of Hypertension.”

• AHA Hypertension, Crystal City, VA, October 8-10. Visit us at Tables 25 and 26. Exhibitor Spotlight at Ballroom A & B on Friday, October 9, from 1:00 to 1:30 p.m.
• ASN Kidney Week, Denver, CO, October 22-24. Visit us at Booth #1023. Exhibitor Spotlight at Theater #3 on Saturday, October 24, from 11:00 to 11:45 a.m.
• AHA Scientific Sessions, Chicago, IL, November 7-9. Visit us at Booth #3014. Exhibitor Spotlight at Learning Studio #3 on Sunday, November 8, from 9:30 to 10:15 a.m.

Notes to the editor

About Dr Michael A. Weber, MD
Dr. Weber is Professor of Medicine at the SUNY Downstate College of Medicine in Brooklyn, New York. He received his medical degree from Sydney University in Australia. His career has been focused primarily on hypertension and preventive cardiology. He has published numerous research articles in medical literature and has authored or edited several books.

Dr. Weber was the Editor-in-Chief of The Journal of Clinical Hypertension for over 10 years. Dr. Weber was one of the founders of The American Society of Hypertension and has served as its President. He also served as Chair of the ASH Hypertension Specialists Program. He is a Fellow of The American College of Physicians, The American College of Cardiology and The American Heart Association. He has served on the Cardiovascular and Renal Drugs Advisory Board of the Food and Drug Administration. He has also served for ten years as Chairman of the Formulary Committee of a major pharmacy benefits provider serving many of the leading health plans in the United States.

His main current research interests are in clinical trials of patients at high risk of cardiovascular events or strokes. He is also participating actively in trials in patients with metabolic disorders such as diabetes and kidney disease. Dr. Weber currently serves on the Steering Committees of several national and international clinical trials. Dr. Weber serves as a consultant to Idorsia.

About Dr. John M. Flack, MD
Dr. Flack, an Alpha Omega Alpha (AOA) graduate of the University of Oklahoma School of Medicine, is the Sergio Rabinovich Endowed Chair of Internal Medicine and the Professor and Chair of the Departments of Medicine and Population Science at Southern Illinois University School of Medicine. He is also Director of the Hypertension Clinic.

He is a board-certified Internal Medicine specialist and an internationally renowned hypertension specialist/cardiovascular epidemiologist with widely recognized clinical/research expertise in hypertension in African Americans, resistant/refractory hypertension, device-based therapies for hypertension and racial cardiovascular health disparities. Dr. Flack is the current President of the American Hypertension Specialist Certification Program. He has published over 250 peer-reviewed manuscripts and book chapters and is an Associate Editor for the journal Hypertension. He maintains an active clinical practice in complex hypertension at SIU where he teaches and mentors medical students and residents and undertakes innovative, cutting-edge research.

Dr. Flack has received numerous awards including the Distinguished Research Award (1993) from the International Society on Hypertension in Blacks (ISHIB), the Daniel D. Savage Memorial Scientific Award (1998) from the Association of Black Cardiologist (ABC), the F. Dewey Dodrill Award for Excellence (2007) from the American Heart Association (AHA), the Detroit News Michiganian of the Year (2009), and the University of Oklahoma Academic Physician of the Year (2012). Also, he has been repeatedly named to Top Doctor, Best Doctor, and Super Doctor lists. Previously, he served as a voting member of the FDA Cardio-Renal Advisory Board. Dr. Flack was recently conferred the status of Master by the American College of Physicians (ACP); he also previously served as a member of the ACP Board of Regents. Dr. Flack serves as a consultant to Idorsia.

About aprocitentan
Aprocitentan is a once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan is approved as TRYVIO^® in the US for the treatment of systemic hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs, and has been commercially available since October 2024. For more information see the Full Prescribing Information including BOXED Warning (PI and Medication Guide). TRYVIO is now included in the American College of Cardiology’s (ACC) and the American Heart Association’s (AHA) new comprehensive clinical practice guidelines for the management of high blood pressure. Aprocitentan is approved as JERAYGO^™ for the treatment of resistant hypertension in combination with other antihypertensives in the European Union, the UK, Switzerland, and Canada.

About PRECISION^6,7 (NCT03541174)
PRECISION was a multicenter, blinded, randomized, parallel-group, Phase 3 study, which was performed in Europe, North America, Asia, and Australia. Patients were eligible for randomization if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardized background therapy consisting of three antihypertensive drugs, including a diuretic. The study consisted of three sequential parts: Part 1 was the 4-week double-blind, randomized, and placebo-controlled part, in which 730 patients were randomized to aprocitentan 12.5 mg (n=243), aprocitentan 25 mg (n=243), or placebo (n=244) in a 1:1:1 ratio; Part 2 was a 32-week single (patient)-blind part, in which all patients received aprocitentan 25 mg (n=704); and Part 3 was a 12-week double-blind, randomized, and placebo-controlled withdrawal part, in which patients were re-randomized to aprocitentan 25 mg (n=307) or placebo (n=307) in a 1:1 ratio. The primary and key secondary endpoints were changes in unattended office systolic blood pressure from baseline to week 4 and from withdrawal baseline to week 40, respectively. Secondary endpoints included 24-h ambulatory blood pressure changes.

At baseline, 69.2% of patients were obese or severely obese, 54.1% had diabetes, 22.2% had stage 3-4 chronic kidney disease and 19.6% had congestive heart failure. 63% of randomized patients were receiving at least 4 anti-hypertensive therapies at screening.

References

1. Parvanova A, et al. Mechanisms and treatment of obesity-related hypertension. Part 2: Treatments. Clin Kidney J. 2025;18(3):sfaf035. doi:10.1093/ckj/sfaf035.
2. Weil BR, et al. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol. 2011;301(3):H689-H695. doi:10.1152/ajpheart.00206.2011.
3. Mavromatis LA, et al. Epidemiology of cardiovascular-kidney-metabolic syndrome. Nat Rev Nephrol. Published online May 7, 2026. doi:10.1038/s41581-026-01078-w.
4. Chen Y, et al. Prevalence and mortality association of different stages of cardiovascular-kidney-metabolic syndrome. JACC Adv. 2025;4(6 Pt 2):101843. doi:10.1016/j.jacadv.2025.101843.
5. McCormack T, et al. Uncontrolled Hypertension Prevalence, Characteristic Profiles, and Risk of Cardiorenal and Metabolic Outcomes: Insights from the EnligHTN Study. Adv Ther. Published online July 13, 2026. doi:10.1007/s12325-026-03681-6
6. Danaietash P et al. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertension 2022 Jul;24(7):804-813.
7. Schlaich MP, et al. A randomized controlled trial of the dual endothelin antagonist aprocitentan for resistant hypertension. The Lancet, 2022; Dec 3;400(10367):1927-1937.

About Idorsia
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Idorsia has transferred its rights for aprocitentan, cenerimod and selatogrel to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the latest Financial Report.

Attachment

• Press Release PDF

• Ranked as the highest-positioned Mexican company in the Food & Beverage sector in the list compiled by Newsweek and Statista.
• The ranking recognizes 1,000 companies across 20 countries that stand out for earning the trust of their key stakeholders.

MEXICO CITY, Oct. 05, 2026 (GLOBE NEWSWIRE) — Grupo Bimbo, the world’s leading baking company, has been recognized in the World’s Most Trustworthy Companies 2026 ranking, compiled by Newsweek and Statista. The company ranked sixth globally in the Food & Beverage category, climbing 32 positions compared to 2025, when it ranked 38th. This result also makes Grupo Bimbo the highest-ranked Mexican company within the sector.

In this edition, the ranking recognizes 1,000 companies from 20 countries for the trust they generate among their key stakeholders. The results are organized across 23 industries, including Food & Beverage, Consumer Goods, Healthcare & Life Sciences, Energy & Utilities, Retail, Financial Services, Technology, Transportation & Logistics, Media & Entertainment, and Real Estate.

For Grupo Bimbo, this achievement reflects the strong relationships it has built with consumers, associates, and investors, as well as the trust it inspires in the communities where it operates. It also recognizes a legacy founded on consistency, responsibility, and transparency.

This recognition adds to a track record supported by tangible environmental and social achievements. On the sustainability front, Grupo Bimbo has advanced regenerative agriculture practices across more than 500,000 hectares, achieved 100% renewable electricity and water replenishment in its operations, made 99% of its packaging recyclable, and operates more than 8,000 sustainable vehicles, including over 4,000 electric vehicles.

On the social side, the company has developed more than 270 Good Neighbor projects, benefiting over 1.7 million people. Additionally, Grupo Bimbo continues to strengthen its portfolio with more nutritious options: 48% of its sales come from products that meet or exceed optimal nutrition standards, and 100% of its daily-consumption portfolio is now free from artificial colors.

The Criteria Behind the International Recognition

The ranking evaluates trust in companies based on three core pillars:

• Customer trust
• Investor trust
• Employee trust

The methodology included the participation of more than 65,000 individuals across 20 countries, who completed approximately 200,000 company evaluations through an independent survey. The study was complemented by an analysis of public conversation based on more than 320,000 mentions collected from a variety of online information sources to assess public perception and sentiment toward companies. The final score combines 80% survey results and 20% public sentiment analysis.

The list includes publicly traded companies with revenues exceeding US$500 million and headquartered in one of the countries covered by the study.

For Grupo Bimbo, this recognition reflects a level of trust built consistently over more than 80 years of history. From its origins in Mexico to becoming a global company, Grupo Bimbo has maintained a long-term vision and a commitment to building lasting relationships with associates, consumers, investors, and communities. This trust is also the result of a people-centered culture that prioritizes well-being and continues to advance its Purpose of Nourishing a Better World.

About Grupo Bimbo
Grupo Bimbo is the leader and largest baking Company in the world and a relevant participant in snacks. It has a presence in 99 countries worldwide, operating directly in 39 and serving another 60 through strategic partnerships. Its operations span the Americas, Europe, Asia, and Africa, with 250 bakeries and snackeries, and more than 1,600 sales centers. With annual sales of over US$23 billion, the Company offers a diversified product portfolio, its main categories include sliced and artisan bread, buns & rolls, pastries, cakes, cookies, toasts, English muffins, bagels, tortillas & flatbreads, and salty snacks, among others. Grupo Bimbo operates one of the largest direct-store-delivery networks in the world, with more than 55,000 routes and over 152,000 associates. Its shares are listed on the Mexican Stock Exchange (BMV) under the ticker symbol BIMBO, and trade in the U.S. over-the-counter market through a Level 1 ADR under the ticker symbol BMBOY.

Grupo Bimbo Social Media: Sitio web | Facebook | X | LinkedIn | TikTok

Media contact:

Nina Negrin
Buchanan Public Relations
bbu@buchananpr.com

• Ranked as the highest-positioned Mexican company in the Food & Beverage sector in the list compiled by Newsweek and Statista.
• The ranking recognizes 1,000 companies across 20 countries that stand out for earning the trust of their key stakeholders.

MEXICO CITY, Oct. 05, 2026 (GLOBE NEWSWIRE) — Grupo Bimbo, the world’s leading baking company, has been recognized in the World’s Most Trustworthy Companies 2026 ranking, compiled by Newsweek and Statista. The company ranked sixth globally in the Food & Beverage category, climbing 32 positions compared to 2025, when it ranked 38th. This result also makes Grupo Bimbo the highest-ranked Mexican company within the sector.

In this edition, the ranking recognizes 1,000 companies from 20 countries for the trust they generate among their key stakeholders. The results are organized across 23 industries, including Food & Beverage, Consumer Goods, Healthcare & Life Sciences, Energy & Utilities, Retail, Financial Services, Technology, Transportation & Logistics, Media & Entertainment, and Real Estate.

For Grupo Bimbo, this achievement reflects the strong relationships it has built with consumers, associates, and investors, as well as the trust it inspires in the communities where it operates. It also recognizes a legacy founded on consistency, responsibility, and transparency.

This recognition adds to a track record supported by tangible environmental and social achievements. On the sustainability front, Grupo Bimbo has advanced regenerative agriculture practices across more than 500,000 hectares, achieved 100% renewable electricity and water replenishment in its operations, made 99% of its packaging recyclable, and operates more than 8,000 sustainable vehicles, including over 4,000 electric vehicles.

On the social side, the company has developed more than 270 Good Neighbor projects, benefiting over 1.7 million people. Additionally, Grupo Bimbo continues to strengthen its portfolio with more nutritious options: 48% of its sales come from products that meet or exceed optimal nutrition standards, and 100% of its daily-consumption portfolio is now free from artificial colors.

The Criteria Behind the International Recognition

The ranking evaluates trust in companies based on three core pillars:

• Customer trust
• Investor trust
• Employee trust

The methodology included the participation of more than 65,000 individuals across 20 countries, who completed approximately 200,000 company evaluations through an independent survey. The study was complemented by an analysis of public conversation based on more than 320,000 mentions collected from a variety of online information sources to assess public perception and sentiment toward companies. The final score combines 80% survey results and 20% public sentiment analysis.

The list includes publicly traded companies with revenues exceeding US$500 million and headquartered in one of the countries covered by the study.

For Grupo Bimbo, this recognition reflects a level of trust built consistently over more than 80 years of history. From its origins in Mexico to becoming a global company, Grupo Bimbo has maintained a long-term vision and a commitment to building lasting relationships with associates, consumers, investors, and communities. This trust is also the result of a people-centered culture that prioritizes well-being and continues to advance its Purpose of Nourishing a Better World.

About Grupo Bimbo
Grupo Bimbo is the leader and largest baking Company in the world and a relevant participant in snacks. It has a presence in 99 countries worldwide, operating directly in 39 and serving another 60 through strategic partnerships. Its operations span the Americas, Europe, Asia, and Africa, with 250 bakeries and snackeries, and more than 1,600 sales centers. With annual sales of over US$23 billion, the Company offers a diversified product portfolio, its main categories include sliced and artisan bread, buns & rolls, pastries, cakes, cookies, toasts, English muffins, bagels, tortillas & flatbreads, and salty snacks, among others. Grupo Bimbo operates one of the largest direct-store-delivery networks in the world, with more than 55,000 routes and over 152,000 associates. Its shares are listed on the Mexican Stock Exchange (BMV) under the ticker symbol BIMBO, and trade in the U.S. over-the-counter market through a Level 1 ADR under the ticker symbol BMBOY.

Grupo Bimbo Social Media: Sitio web | Facebook | X | LinkedIn | TikTok

Media contact:

Nina Negrin
Buchanan Public Relations
bbu@buchananpr.com

Milwaukee, WI, Oct. 05, 2026 (GLOBE NEWSWIRE) — WEYCO Group, Inc. (NASDAQ: WEYS), a global marketer of footwear, plans to announce third quarter 2026 financial results after the close on Tuesday, November 3, 2026.  Additionally, Thomas W. Florsheim, Jr., Chairman and CEO, will host a conference call on Wednesday, November 4, 2026, at 11:00 a.m. Eastern Time to discuss the financial results in more detail.

To participate in the call, you will first need to pre-register online. Pre-registration takes only a few minutes and you may pre-register at any time, including up to and after the call start time. To pre-register, please go to: https://register-conf.media-server.com/register/BI848ca1b1750c4cf39796a8f3b93fc1a7. The pre-registration process will provide the conference call phone number and a passcode required to enter the call.

A replay will be available for one year beginning about two hours after the completion of the call at the following webcast link: https://edge.media-server.com/mmc/p/s6dttjz4. Alternatively, the replay will be available by visiting the investor relations section of Weyco Group’s website at www.weycogroup.com.

Weyco Group, Inc. designs and markets quality and innovative footwear principally for men, but also for women and children, under a portfolio of well-recognized brand names including: Florsheim, Nunn Bush, Stacy Adams, and BOGS. The Company’s products can be found in leading footwear, department, and specialty stores, as well as on e-commerce websites worldwide. Weyco Group also operates Florsheim concept stores in the United States and Australia, as well as in a variety of international markets.

CONTACT: Investor Relations Contact
Judy Anderson (414) 908-1833
Investor.Relations@WeycoGroup.com

Milwaukee, WI, Oct. 05, 2026 (GLOBE NEWSWIRE) — WEYCO Group, Inc. (NASDAQ: WEYS), a global marketer of footwear, plans to announce third quarter 2026 financial results after the close on Tuesday, November 3, 2026.  Additionally, Thomas W. Florsheim, Jr., Chairman and CEO, will host a conference call on Wednesday, November 4, 2026, at 11:00 a.m. Eastern Time to discuss the financial results in more detail.

To participate in the call, you will first need to pre-register online. Pre-registration takes only a few minutes and you may pre-register at any time, including up to and after the call start time. To pre-register, please go to: https://register-conf.media-server.com/register/BI848ca1b1750c4cf39796a8f3b93fc1a7. The pre-registration process will provide the conference call phone number and a passcode required to enter the call.

A replay will be available for one year beginning about two hours after the completion of the call at the following webcast link: https://edge.media-server.com/mmc/p/s6dttjz4. Alternatively, the replay will be available by visiting the investor relations section of Weyco Group’s website at www.weycogroup.com.

Weyco Group, Inc. designs and markets quality and innovative footwear principally for men, but also for women and children, under a portfolio of well-recognized brand names including: Florsheim, Nunn Bush, Stacy Adams, and BOGS. The Company’s products can be found in leading footwear, department, and specialty stores, as well as on e-commerce websites worldwide. Weyco Group also operates Florsheim concept stores in the United States and Australia, as well as in a variety of international markets.

CONTACT: Investor Relations Contact
Judy Anderson (414) 908-1833
Investor.Relations@WeycoGroup.com

MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (TSXV: CDPR) OTCQX CDPMF) (BVL: CDPR) (“CDPR” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders (the “Meeting”), held on September 30, 2026.

A total of 345,835,894 common shares, representing 52.06% of the Company’s issued and outstanding common shares as of the record date, were represented in person or by proxy at the Meeting.

All matters submitted to shareholders for approval were approved, namely the election of each director nominee with at least 85% of the votes cast in favour and the appointment of Davidson & Company LLP as the Company’s independent auditors with 100% of the votes cast in favour.

Election of Directors

Shareholders elected the following eight directors to the Company’s Board of Directors: John G. Booth, René Branchaud, John S. Carr, Guy Goulet, Frank Hodgson, Manuel Lizandro Rodriguez, Lara J.T. Smith and Steven Zadka.

Steven Zadka, Executive Chairman and Director, commented: “On behalf of the Board, I would like to thank Pyers Griffith, who did not stand for re-election, for his valuable contributions and insights during his tenure as a director. We look forward to his continued contribution to the Company as Chief Strategy Officer.”

Cerro de Pasco Resources

Cerro de Pasco Resources Inc. is focused on developing its 100%-owned El Metalurgista mining concession in central Peru, which hosts silver-rich tailings and stockpiles accumulated over more than a century of mining in one of the most prolific polymetallic districts in the Americas. The Company’s strategy is to reprocess historic mining waste to recover value while addressing the long-term environmental liabilities associated with these tailings.

For more information, please visit www.pascoresources.com.

Further Information

Donna Yoshimatsu, VP Investor Relations
Mobile: +1 416-722-2456
dyoshi@pascoresources.com 

“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

This press release was published by a CLEAR® Verified individual.